Trial · NCT07226531
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient demographics characteristics: race | Baseline | Number of percentages of patients by race |
| Primary | Patient demographics characteristics: sex, age at initial AA diagnosis, geographic location of patient's treating dermatologist, insurance type | "Baseline" or "Day 1" | Number of percentages of patients by sex |
| Primary | Patient demographics characteristics: age at initial AA diagnosis | "Baseline" or "Day 1" | Number of percentages of patients by age at initial AA diagnosis |
| Primary | Patient demographics characteristics: geographic location of patient's treating dermatologist | "Baseline" or "Day 1" | Number of percentages of patients by geographic location of patient's treating dermatologist |
| Primary | Patient demographics characteristics: insurance type | "Baseline" or "Day 1" | Number of percentages of patients by insurance type |
| Primary | Patient clinical characteristics at initial AA diagnosis: AA disease activity | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: AA disease activity |
| Primary | Patient clinical characteristics at initial AA diagnosis: SALT score | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: SALT score |
| Primary | Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score |
| Primary | Patient clinical characteristics at initial AA diagnosis: eyebrow involvement | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: eyebrow involvement |
| Primary | Patient clinical characteristics at initial AA diagnosis: eyelash involvement | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: eyelash involvement |
| Primary | Patient clinical characteristics at initial AA diagnosis: beard involvement | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: beard involvement |
| Primary | Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations | "Baseline" or "Day 1" | Number of percentages of Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations |
| Primary | Patient treatment history: Additional treatment classes received during ritlecitinib treatment, additional treatment classes received after discontinuation of ritlecitinib, duration of each treatment class | "Day 1 through study completion, a minimum of 6-months follow-up" | |
| Primary | Characteristics of ritlecitinib treatment: Total duration of ritlecitinib exposure, reasons for ritlecitinib discontinuation (if ritlecitinib treatment stopped before last known clinic visit), | "Day 1 through study completion, a minimum of 6-months follow-up" | |
| Primary | Real-world clinical outcomes of ritlecitinib treatment: AA disease activity | "Day 1 through study completion, a minimum of 6-months follow-up" | AA disease activity reported as active hair loss or inactive hair loss |
| Primary | Real-world clinical outcomes of ritlecitinib treatment: SALT score overall change from baseline | "Day 1 through study completion, a minimum of 6-months follow-up" | SALT score overall change from baseline (i.e., to last observed clinic visit), as well as change from baseline to predefined post-index time points (6-, 12-, 18-, and 24-months post-index, or other relevant timepoints based on actual distribution of data). Numeric and Categorical Data: no reduction from baseline, \>0%-≤25% SALT reduction, \>25%-≤50% SALT reduction, \>50%-≤75% SALT reduction, \>75% SALT reduction; Yes/No indicator for ≥30% SALT reduction; other categories/thresholds may also be applied. |
| Primary | Real-world clinical outcomes of ritlecitinib treatment: SALT score | "Day 1 through study completion, a minimum of 6-months follow-up" | Numeric data, with categorical values of \<50. 50-75, 75-100, and additional categories for ≥50 (to define severe AA) and 95-100 (to defined very severe AA); alternative categories may also be applied. |
| Primary | Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving SALT ≤20 and ≤10 | "Day 1 through study completion, a minimum of 6-months follow-up" | Landmark probabilities of achieving SALT≤20 and SALT≤10 at 6-, 12-, 18-, and 24-months post-index date, or other relevant timepoints based on actual distribution of data. |
| Primary | Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving a sustained SALT response | "Day 1 through study completion, a minimum of 6-months follow-up" | Landmark probabilities of achieving a sustained SALT response at 6-, 12-, 18-, and 24-months post-index date, or other relevant timepoints based on actual distribution of data |
| Primary | Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving ≥30% SALT score reduction from baseline at 6-, 12-, 18-, and 24-months post-index date | "Day 1 through study completion, a minimum of 6-months follow-up" |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07226531/registered